Oura has agreed to purchase Counsel Health — a primary care startup built around artificial intelligence — for approximately $625 million. The deal follows Oura’s recent decision to indefinitely delay its planned IPO, which had been estimated at up to $2.2 billion, citing volatility in the public markets.
How the Integration Works
Counsel Health combines a chat-based AI medical assistant with access to licensed physicians. In June, Oura already added Counsel’s service into its wellness app, allowing users to get personalized medical guidance or speak directly with a doctor as needed. With the acquisition, Oura aims to broaden its medical services, offering preventive care, acute care, and support for chronic and specialist conditions.
Strategic Moves & Financials
At the closing of the deal — expected before the end of 2027 — Counsel’s leadership and team will join Oura. Counsel CEO Muthu Alagappan is set to become Oura’s Chief Clinical AI Officer, and about 70 Counsel employees will be onboarded. Despite its relatively early stage, Counsel has raised $25 million in Series A funding in the past year, primarily through backers like a16z and GV, with a total funding amount close to $36 million.
Meanwhile, Oura continues seeing strong momentum. In the quarter ending September 30, its revenue surged 153% year over year to $533 million. For fiscal year 2026, it reported $1.75 billion in revenue, up nearly 92% from the previous year. The company’s valuation stands at $11 billion following a $900 million funding round in October 2025.
Oura’s move into AI-driven healthcare comes at a moment when its dominance in the smart ring market is being challenged by newcomers like RingConn and Ultrahuman. Adding medical care reinforces its wearable-based wellness offerings and deepens engagement beyond biometrics and sleep tracking.
From both sides, confidence is being placed in the combined platform: Oura’s data offers objective, longitudinal health metrics, while Counsel brings clinical AI and physician oversight. Together, the goal is to offer more informed, holistic care to users.
This deal represents a major push for Oura beyond hardware and wearables toward becoming a broader health platform. It reflects a larger trend in wellness tech — turning devices and sensors into gateways for access, not just insight.
Analysis: This acquisition marks a turning point for Oura. It shows the company is doubling down on health services as a core differentiator, especially given its delayed IPO. By embedding AI-powered care and bringing licensed clinicians into the fold, Oura positions itself not merely as a biometrics company but as a contender in digital health. What to watch: how Oura integrates Counsel’s model without compromising clinical safety, and whether this strategy helps it fend off wearables rivals who may focus only on hardware advances.
